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PENILAIAN RISIKO PENDARAHAN GASTROINTESTINAL 
MENGGUNAKAN HAS-BLED DALAM PESAKIT FIBRILASI 
ATRIAL YANG MENERIMA WARFARIN DI 
HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRAK 
Terdapat peningkatan penggunaan antikoagulan dalam kalangan pesakit fibrilasi atrial di 
seluruh dunia. Warfarin menjadi antikoagulan yang paling lazim digunakan. Sejurus 
sebelum memulakan rawatan, risiko pendarahan perlu dinilai untuk meminimakan risiko 
pesakit mengalami pendarahan. HAS-BLED adalah ringkas dan selamat digunakan. 
Walaubagaimanapun, penggunaan HAS-BLED sejurus sebelum memulakan 
antikoagulan masih tidak diketahui. 
Kajian ini telah diadakan untuk menilai penggunaan HAS-BLED dan kesannya 
ke atas kejadian pendarahan gastrointestinal (GI). Kajian retrospektif ini dijalankan dalam 
kalangan pesakit fibrilasi atrial yang menghadiri klinik pesakit luar INR atau KRK di 
antara Januari 2011 sehingga Disember 2017. 88 pesakit layak menjalani kajian ini dan 
HAS-BLED mereka telah dinilai. Pesakit berusia 18 tahun ke atas dengan fibrilasi atrial 
yang menerima warfarin dimasukkan dalam kajian ini. Kriteria penyisihan termasuk 
mereka yang mengambil warfarin untuk sebab selain daripada fibrilasi atrial. Kami 
menyasarkan untuk menentukan perkaitan di antara pendarahan GI dan AF dalam 
kalangan pesakit yang ada dan tiada HAS-BLED. 
Di antara 88 pesakit yang dipilih, kadar kejadian pendarahan GI adalah 5.7 kes 
per 100 tahun pesakit. 44 (50%) pernah membuat penilaian HAS-BLED sejurus sebelum 






dengan jantina pembahagian jantina yang sama rata. 83 (94.1%) pesakit yang memulakan 
warfarin mempunyai skor CHA2DS2 VASc ≥2. Pendarahan GI berlaku dalam 11 (12.5%) 
daripada 88 pesakit. 6 (13.6%) pesakit mempunyai HAS-BLED dan 5 (11.4%) termasuk 
dalam kumpulan berisiko tinggi. Purata HAS-BLED di kalangan 44 pesakit adalah 1.92 
(±0.936) dan purata HAS-BLED di kalangan 6 pesakit yang mengalami pendarahan 
gastrointestinal adalah lebih tinggi iaitu 2.83 (±0.98). Kadar pendarahan gastrointestinal 
bagi setiap 100 pesakit-tahun adalah 0.53 dan 2.63 bagi markah HAS-BLED 1 dan 3. 
Tiada perkaitan di antara pendarahan GI dan HAS-BLED nilai p=0.747). Terdapat 
perkaitan di antara pendarahan GI dan jangka masa pengambilan warfarin kurang 
daripada 30 hari (nilai p=<0.005). 
 Kesimpulannya, kadar penggunaan HAS-BLED masih rendah. Didapati tiada 
perkaitan di antara HAS-BLED dan pendarahan GI. Walaubagaimanapun, HAS-BLED 
adalah penting untuk menentukan faktor risiko boleh ubah sejurus sebelum memulakan 















GASTROINTESTINAL BLEEDING RISK ASSESSMENT USING 
HAS-BLED IN ATRIAL FIBRILLATION PATIENTS WHO ARE 
RECEIVING WARFARIN IN 
HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRACT 
There has been an increase usage of anticoagulant among atrial fibrillation worldwide. 
Warfarin remains one of the commonest anticoagulant use. Prior to starting treatment, 
bleeding risk need to be assess in order to minimize patients’ risk of bleeding. HAS-
BLED is a simple and user friendly to use. Unfortunately, the utilization and usage of 
HAS-BLED prior to starting anticoagulant in HUSM was not known and not yet being 
studied.  
This study had been done to assess utilization of HAS-BLED and its impact on the 
occurrence of gastrointestinal bleeding (GIB). This retrospective study was performed 
among atrial fibrillation (AF) patients who attended INR or KRK outpatient clinic 
between January 2011 to December 2017. 88 patients were eligible for this study and 
their HAS-BLED were assess. Patients above 18 years old with AF who received warfarin 
were included in this study. Exclusion criteria include those who were taking warfarin for 
other causes than atrial fibrillation. We aimed to determine the rate of GIB among AF 
patients who are on warfarin, assess GIB risk using HAS-BLED and determine the 






Among the selected 88 patients, the incidence rate of GIB is 5.7 cases per 100 patient-
years. 44 (50%) had HAS-BLED assessment done prior to starting anticoagulant. The 
mean age of those who received warfarin was 64 years old with gender equally 
distributed. 83 (94.1%) patients who were started on warfarin had CHA2DS2 VASc score 
≥2. GIB occurred in 11 (12.5%) out of 88 patients. Six (13.6%) patients were with HAS-
BLED and 5 (11.4%) belong to the high risk group. The mean score for 44 patients with 
HAS-BLED was 1.92 (±0.936) and the mean score for 6 patients with GIB was much 
higher that was 2.83 (±0.98). The bleeding rate for every 100 patient-years was 0.53 and 
2.63 for HAS-BLED score of 1 and 3 respectively. There was no association between 
GIB and HAS-BLED (p value= 0.747). There was association between GIB and duration 
of warfarin intake less than 30 days (p value <0.005). 
In conclusion, the utilisation of HAS-BLED remains low. There is no association 
between HAS-BLED and GIB. However, HAS-BLED is important to determine 











CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 Atrial Fibrillation and Stroke 
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia commonly found in 
general population. It defined as irregularly irregular pattern with no distinct p waves 
recorded in the electrocardiographic (ECG) (Kapil Kumar MD, 2017). It caused mainly 
attributed to the single focus firing rapidly in the atria and the most common site is the 
pulmonary veins. Stretching of the atrial heart chamber increase the propensity for rapid 
firing as a result of stretch sensitive ion channels (Kalifa et al., 2003). 
According to Lim et al. prevalence of AF among Malaysian population is 0.54%. 
The prevalence rate are much higher in the US and UK which is 0.94% and 2.0% 
respectively (Lim et al., 2016). In ECHOES trial,  the prevalence for AF is higher in men 
(2.4%) compared to women (1.6%) (Davis et al., 2012). This is comparable to Malaysian 
population conferring to REDISCOVER study where they found that prevalence among 
men is higher (58.5%) and women (41.5%) (Lim et al., 2016). AF prevalence also 
increase with increasing age (Magnani et al., 2011). 
 Clinical manifestation of AF varied from asymptomatic, palpitation, dyspnea, 
angina and infrequently, syncope. To highlight one of the most significant clinical 
features related to AF is stroke. AF is associated with 3 to 5-fold increase risk of stroke 
(Wolf et al., 1991). When AF occurred, the dysrhythmia causing contractile dysfunction, 
stasis and blood clot formation that later increased the risk of thromboembolism or 
cardioembolic stroke (Kamel et al., 2016). In addition, there are other systemic risk 
factors that increase the stroke risk via other mechanism outside the atrium such as in-






Stroke is the number 2 cause of death worldwide after ischemic heart disease 
(World Health Organization, 2017). Stroke patients with AF are at high risk of death both 
at the acute phase of stroke and during the subsequent year after the first acute stroke 
event. Mortality from cardiac diseases prevailed in the AF group during the acute phase 
of stroke (Kaarisalo et al., 1997). 
Stroke with AF also has worst prognosis than patients without AF (Steger et al., 
2004). Due to increase morbidity and mortality among AF patients, guidelines had been 
established to determine AF patients who are at risk of developing stroke. Guidelines has 
been made since 2 decades ago to determine AF patients who will benefit from oral 
anticoagulant. In 2001, Gage et al. had published a paper on validation of clinical 
classification schemes for predicting stroke in patients with atrial fibrillation; namely 
CHADS2 (Gage et al., 2004; Gage et al., 2001). The risk stratification was being refined 
further in 2010 to include few other important risk factors, which is known as CHA2DS2 
VASc (Lip et al., 2010). With increasing risk factors, there is increased risk of having 
stroke. In recent European Society of Cardiology (ESC) guideline for the management of 
AF published in 2016, (Kirchhof et al., 2016) anticoagulant should be considered in those 
with CHA2DS2 VASc score of ≥1 and obviously indicated if the score is ≥2. 
1.2 Stroke Prevention Therapy In Atrial Fibrillation Patients 
1.2.1 Warfarin or Vitamin K Antagonists 
First found by L M Roderick in North Dakota in 1929, warfarin was created from 
mouldy silage made from sweet clover (Melilotus alba and M. officinalis). It showed that 
it contained a haemorrhagic factor that reduced the activity of prothrombin. However, it 
was not until 1940 that Karl Link and his student Harold Campbell in Wisconsin 






coumarin) (Kresge et al., 2005). Further work by Link led in 1948 to the synthesis of 
warfarin, which was initially approved as a rodenticide in the USA in 1952, and then for 
human use in 1954. The name warfarin is derived from WARF (Wisconsin Alumni 
Research Foundation) and –arin from coumarin (Pirmohamed, 2006).  
 In this study, we chose to study warfarin because warfarin is the most widely used 
anticoagulant in the world. Warfarin is a highly effective treatment for the reduction of 
stroke in atrial fibrillation (AF) and its limitations are well studied. Despite the advent of 
non-vitamin K antagonist (VKA) oral anticoagulant drugs (NOACs), warfarin will 
always be the most relevant suitable drugs to be used since its introduction in 1954 due 
to various factors. It is easily available, cheaper, mechanism of action is well understood, 
reversal agents extensively accessible, and suitable to almost all patients. In the UK it has 
been estimated that at least 1% of the whole population and 8% of those aged over 80 
years are taking warfarin (Wadelius and Pirmohamed, 2007).  
Warfarin acts as an antagonist of vitamin K, inhibiting reductases involved in the 
synthesis of hydroquinone from epoxide, particularly epoxide-reductase (Figure 1). The 
inhibition of cyclic conversion of vitamin K induces the hepatic production and secretion 
of decarboxylated or partially carboxylated proteins that represent 10 to 40% of normal 








Figure 1: Cycle of Vitamin K and Its Inhibition by Warfarin 
Source: Warfarin: pharmacological profile and drug interactions with antidepressant. 
Einstein 2012 (Souto Teles et al., 2012). 
The main adverse effect associated with warfarin is bleeding. Major and fatal 
bleeding events occur respectively at rates of 7.2 and 1.3 per 100 patient-years, according 
to a meta-analysis of 33 studies (Linkins et al., 2003). The reported occurrence of 
intracranial hemorrhage (ICH), which represents the mostly feared bleeding complication 
of VKA therapy because of its high disability and/or fatality rate, is in the range of 0.2%-
0.4% per year (Schulman et al., 2008). 
Warfarin is also number three on the list of drugs implicated in causing hospital 
admission through adverse effects (Pirmohamed et al., 2004). Warfarin’s narrow 
therapeutic index makes it difficult to maintain patients within a defined anticoagulation 
range. Due to difficulties to maintain INR within target range and frequency of follow up 
to out- patient clinic, it leads to the emergence of new oral anticoagulant drugs that can 








1.2.2 Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) Drugs 
In the last few years, emerging novel oral anticoagulants or NOACs (comprising 
apixaban (Eliquis®), edoxaban (Lixiana), rivaroxaban (Xarelto®) factor Xa inhibitors 
and dabigatran (Pradaxa®) direct thrombin inhibitor, have been used in patients with non-
valvular atrial fibrillation as suitable alternatives to the perpetual warfarin and analogues 
(vitamin K antagonists or VKAs) to prevent stroke and venous thromboembolism (VTE). 
The major trials of NOACs in AF were: ARISTOTLE, ENGAGE-AF, Rocket-AF and 
RE-LY, respectively (Connolly et al., 2009a; Giugliano et al., 2013; Granger et al., 2011; 
Patel et al., 2011). NOACs are presently contraindicated in patients with mechanical heart 
valves, following several reports of valve thrombosis (Chu et al., 2012; Kuwauchi et al., 
2013; Price et al., 2012). 
In a nationwide registry study to compare bleeding rates in patients with AF being 
prescribed oral anticoagulant, the author found out that risk of gastrointestinal bleeding 




Figure 2: Forest plot showing the hazard ratios for first bleeding episode for dabigatran, 
rivaroxaban and apixaban compared with warfarin. Crude IR for first bleeding episode 
are given as events per 100 person-years. CI, confidence interval; GI, gastrointestinal; 
HR, adjusted hazard ratio; IR, incidence rate; OAC, oral anticoagulant. 
Source: A Nationwide Registry Study To Compare Bleeding Rates in Patients With AF 






The most common disadvantage of NOACs is the lack of an antidote to resolve 
major bleeding complications possibly associated with their ubiquitous use. Other than 
Idarucizumab (antidote for Dabigatran) (FDA Office of Hematology and Oncology 
Products, 2015), there are still no specific antidote available for other NOACs. Another 
major concern is the periprocedural management of patients on NOACs which is a 
common complex clinical problem and may pose a patient-specific concern. The third 
disadvantage is cost of each NOAC calculated as total daily cost and in comparison with 
warfarin. Furthermore, ensuring adherence to therapy is important to ensure patients get 
the greatest benefit by using NOACs. When using NOACs, there is no need for 
therapeutic monitoring. Although this is proven to be beneficial in those patients who 
have problems to come for regular follow up to the clinics, it is challenging for clinicians 
to ensure patient adherence. Poor adherence to therapy is a common problem, with typical 
adherence rates for prescribed medications to be approximately 50% (Nieuwlaat et al., 
2014). As NOACs have shorter half-lives than warfarin, close adherence to dosing 
regimens is needed to ensure the drug concentrations remains therapeutic. As a result, 
alternative measures of anticoagulation for assessing recent adherence are needed for the 
NOACs. Some drugs regimens for NOACs are bid dosing, and this may impact patient 
adherence, as in chronic patients, they generally adhere better to od compared with bid 
regimens, which might suggest a potential advantage of rivaroxaban compared with 
dabigatran and apixaban (Savelieva and Camm, 2014). Although INR monitoring during 
VKA therapy is a requirement and not an adherence tool, it does provide an indirect 
measure of adherence.  Most NOACs are renal eliminated. It should be emphasized that 
there are no clinical data for the NOACs in patients on dialysis and the use of NOACs in 
this population is not recommended (Verma et al., 2014). The Canadian Cardiovascular 






when creatinine clearance (CrCl) is <30ml/min (Turpie et al., 2017). This 
recommendations is similar to FDA for patients with renal impairment, however the FDA 
has extrapolated the data from the clinical trials and approved a low dose dabigatran 
(75mg bid), apixaban (5mg bid or 2.5mg bid) and rivaroxaban (15mg od) for patients 
with AF and CrCl of 15-30ml/min (Turpie et al., 2017).  
1.2.3 Left Atrial Appendage Occlusion 
Left atrial appendage (LAA) occlusion may also reduce stroke risk in patients 
with contraindications to oral anticoagulant. Only one device (Watchmanw) has been 
compared with vitamin K antagonist therapy in randomized trials [PROTECT AF 
(Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF 
trial), and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA 
Closure Device In Patients with AF Versus Long Term Warfarin Therapy trial)].In these 
data sets, LAA occlusion was non-inferior to VKA treatment for the prevention of stroke 
in AF patients with moderate stroke risk, with a possibility of lower bleeding rates in the 
patients who continued follow-up (Holmes Jr et al., 2014). Surgical occlusion also may 
be considered during concomitant cardiac surgery. 
 
1.3 Assessment prior to starting anticoagulant 
1.3.1 Indications using CHA2DS2 VASc  
Since CHADS2 being introduced in 2001 and further redefined by Lip et al. in 
2010, the usage of CHA2DS2 VASc score has been used to classify AF patients into stroke 
risk. It is a scoring system consists of clinical risk factor for stroke, introduced in the ESC 
guideline since 2010. It is used to guide clinicians in making initial decision to start oral 






signs/symptoms of heart failure or objective evidence of reduced left ventricular ejection 
fraction) (1 point), Hypertension (Resting blood pressure >140/90 mmHg on at least two 
occasions or current antihypertensive treatment) (1 point), Age 75 years or older (2 
points), Diabetes mellitus (Fasting glucose >125 mg/dL (7 mmol/L) or treatment with 
oral hypoglycaemic agent and/or insulin (1 point), Previous stroke, transient ischaemic 
attack, or thromboembolism (2 points), Vascular disease, Previous myocardial infarction, 
peripheral artery disease, or aortic plaque (1point), Age 65–74 years (1 point), and Sex 
category (female) (1 point) (Kirchhof, 2016). Score of 1 should be considered for 
anticoagulant and score of ≥2 is indicated for anticoagulant in AF patients. If patient is 
contraindicated for anticoagulant, left atrial appendage occluding device may be 
considered (Kirchhof, 2016). Table 1 and 2 describe the CHA2DS2 VASc and adjusted 
















Table 1: CHA2DS2 VASc risk factor score 
 
Table 2: Adjusted stroke rate according to CHA2DS2 VASc 
 
Table 1 and 2 are adapted from Guidelines for the management of atrial fibrillation: the 
Task Force for the Management of Atrial Fibrillation of the European Society of 
Cardiology (ESC) (Camm et al., 2010). 
Risk factor Score 
 
Congestive heart failure/LV dysfunction 1 
Hypertension 1 
Age ≥75 2 
Diabetes mellitus 1 
Stroke/TIA/thromboembolism 2 
Vascular disease- prior myocardial 




Age 65-74 1 
Sex category- female 1 
Maximum score 9 
CHA2DS2 VASc Patients (n=7329) Adjusted stroke rate 
(%/year) 
 
0 1 0% 
1 422 1.3% 
2 1230 2.2% 
3 1730 3.2% 
4 1718 4.0% 
5 1159 6.7% 
6 679 9.8% 
7 294 9.6% 
8 82 6.7% 






1.3.2 Bleeding risk assessment 
1.3.2.1 HAS-BLED  
From the time when the administration of warfarin as primary prevention for 
stroke has been implemented, usage of anticoagulant has dramatically increase. Practise 
of prescribing anticoagulant and looking at the impact and complications exclusively 
bleeding has already become ‘the bread and butter’ in medical care during the course of 
patient’s treatment.  Clinical decision on justification for the usage of anticoagulant is 
based on stroke risk using CHA2DS2 VASc score. Since stroke risk is also closely related 
to bleeding risk (Nieuwlaat et al., 2006), thus HAS-BLED score has been created to assist 
in clinical decision making. Pister et al (2010) used the large population database from 
the prospective Euro Heart Survey on AF, with data collected between 2003 and 2004. 
5333 patients were enrolled and 1 year follow up assessment were performed to determine 
survival and major adverse cardiovascular events, such as major bleeding. From this data, 
they create a novel friendly score name HAS-BLED by incorporating significant risk 
factors found in their derivation cohort as well as risk factor for major bleeding found in 
the literature from systematic reviews (Pisters et al., 2010). The name used an acronym 
and each letter constitutes to 1 parameter which are included as a bleeding risk. Each 
component is given 1 mark each: Hypertension (uncontrolled; defined as systolic blood 
pressure persistently >160), Abnormal renal function (presence of chronic dialysis, renal 
transplantation, or serum creatinine ≥200 micromol/L), Abnormal liver function (chronic 
hepatic disease i.e. cirrhosis, biochemical evidence of significant hepatic derangement e.g 
bilirubin >2x upper limit normal in association with aspartate aminotransferase/ alanine 
aminotransferase/ alkaline phosphatase >3x upper limit normal and so forth), Stroke 






Labile international normalized ratio (INR) (i.e therapeutic time in range <60%), Elderly 
(>65 years), Drugs/alcohol concomitantly (antiplatelet agents, NSAIDs, 1 point for drugs 
and 1 point for alcohol excess). 
Those with score three or more are high risk of bleeding, score zero to two are 
classified into intermediate and low risk of bleeding (Kirchhof, 2016). Score of three and 
above had risk of 3.74 bleeds per 100 patient-years (Pisters et al., 2010).  The annual 
bleeding rate increased with the addition of risk factor from the derivation cohort. Table 
3 and 4 showed HAS-BLED score and risk of major bleeding respectively.  
 
Table 3 : Bleeding risk assessment- HAS-BLED  
Letter Clinical Characteristic Points awarded 
H Hypertension 1 
A Abnormal renal and liver function (1 
point each) 
1 or 2 
S Stroke 1 
B Bleeding 1 
L Labile INRs 1 
E Elderly 1 
D Drugs or alcohol (1 point each) 1 or 2 
HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or 
predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol 









Table 4: The Risk Of Major Bleeding Within 1 Year In Patients With AF Enrolled In 
The Euro Heart Survey 
Risk 
factor/Score 
Number of patients Number of bleeds Risk of bleeds per 100 
Patient-Years 
 
0 798 9 1.13 
1 1286 13 1.02 
2 744 14 1.88 
3 187 7 3.74 
4 46 4 8.70 
5 8 1 12.50 
6 2 0 0.0 
7 0 0 … 
8 0 0 … 
9 0 0 … 
Any score 3071 48 1.56 
P value for 
trend 
  0.007 
Adapted from A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk Of 
Major Bleeding In Patients With Atrial Fibrillation : The Euro Heart Survey (Pisters et 
al., 2010). 
Using bleeding risk assessment is to ensure that administration of anticoagulant is 
justified and their bleeding risk assessed and addressed. The utmost important in 
managing patients with AF is to maximize appropriate antithrombotic therapy and 
minimize adverse events. HAS-BLED is a novel user-friendly score created in 2010. It is 
made to estimate 1-year risk of major bleeding (intracranial, hospitalization, hemoglobin 
decrease >2g/L, and/or transfusion). HAS-BLED is said to be more user-friendly for 
clinical application, all risk factors of HAS-BLED score are readily available from the 







One of the important impact of using HAS-BLED is based on several studies. 
Konishi et al. used HAS-BLED score to assess long-term outcome after percutaneous 
coronary intervention (PCI) in patients taking dual antiplatelet therapy. From 1207 
patients that had undergone PCI using drug eluting stent, they found that incidence of 
both death and major bleeding higher in the high HAS-BLED group (score ≥3) than in 
the low risk group (score 0-2) independent of the presence of AF (Konishi et al., 2015).   
In 2009, Connolly et al. investigate the hypothesis that addition of clopidogrel to 
aspirin would reduce the risk of stroke. A total of 7554 patients recruited who was deemed 
unsuitable for anticoagulant was given either clopidogrel or placebo, in addition to 
aspirin. In half (n=~3500) patients with high stroke risk, the most common applied 
classification was “unsuitable for oral anticoagulant”, which was solely based on 
physician clinical judgement, without the presence of any predefined risk factor of 
bleeding or other objective risk scoring (Connolly et al., 2009b). This reflects physicians’ 
uncertainty about what to consider true risk factors of bleeding. With HAS-BLED, 
decision making will be more objective and fear of starting anticoagulant due to bleeding 
can be curtail. Chia et al. (2016) mentioned that anticoagulation management of AF 
patients among Singaporean population remains inadequate. From 62% AF patients who 
had CHA2DS2 VASc of ≥2, only 32% patients were given anticoagulant. Thus, their study 
recommended that objective assessment of bleeding risks should be performed before 
withholding anticoagulation.  
HAS-BLED has been used in many clinical trials since 2011. The predictive 
performance of major bleeding using this score is better (Apostolakis et al., 2012; 
Beltrame et al., 2017; Gallego et al., 2012; Guo et al., 2016; Zhu et al., 2015) leading to 
many clinical trials use HAS-BLED in assessing bleeding risk in their studies (Kirchhof, 






BLED score not only performs better than the other two scoring systems 
(HEMORR2HAGES and ATRIA), it is also simple and easy to use.  Although HAS-
BLED has been validated in several population cohorts mainly from Europe, there are 
limited data in Asian cohorts (Guo et al., 2013). As we know, bleeding risk among Asian 
population is differ from Europe. Asian population with AF may have different clinical 
profile related stroke risk that renders them to have higher bleeding risk especially 
intracranial haemorrhage (ICH) (Guo et al., 2016). In Taiwanese cohort without 
anticoagulant therapy, the incidence of major bleeding events and ICH 4.5 per 100-person 
years and 0.87% per person-years respectively. These rates may be higher than reported 
rates from clinical trials or non-Asian population (Guo et al., 2016). According to Laila 
et al., knowledge regarding oral anticoagulant among our population remains low 
(Matalqah et al., 2013). Poor knowledge leads to reduce number of patients achieving 
time to therapeutic range (TTR; define as proportion of person-time within the target 
therapeutic range over the total person-time of follow up) >75%. With labile INR (define 
as TTR <75%), this further predispose them to bleeding. It is important to note that the 
prevalence of AF among stroke patients in Malaysia is 10.6% (Chee, 2014). Stroke 
patients with AF were observed to have a higher mortality rate and disability upon 
discharge. Although this is well known, Chia et al. found only 32.7% of AF patients with 
CHADS2 ≥2 were eventually prescribed warfarin (Chia et al., 2016). Elderly women 
were less likely to be given warfarin, presumably because of perceived high bleeding risk. 
Therefore, this study is important to be done in our population in order see the practice of 
using HAS-BLED score as well as to look at objective evidence of gastrointestinal 
bleeding with respect to the HAS-BLED score.  
 Furthermore, those with high bleeding risk can be flagged up and follow up more 






know that stroke is one of the top ten causes of death worldwide (World Health 
Organization, 2017), prevention of stroke is noteworthy than omitting anticoagulant.  
 
1.3.2.2 Other bleeding risk scoring system 
1.3.2.2.1 HEMORR2HAGES 
This score was created in 2006. It comprise of: Hepatic or renal disease, ethanol abuse, 
malignancy, older age (>75 years), reduced platelet cound or function, hypertension 
(uncontrolled), anemia, genetic factors, excessive fall risk and stroke (Gage et al., 2006). 
With each additional point, the rate of bleeding per 100 patient- years of warfarin 
increase: 1.9 for 0, 2.5 for 1, 5.3 for 2, 8.4 for 3, 10.4 for 4 and 12.3 for ≥5 points. 
1.3.2.2. ATRIA  
ATRIA stands for AnTicoagulation and Risk factors In Atrial fibrillation. The paper 
published in 2011 in Journal of American Cardiology. The components that being 
assessed in the score are: anemia (3 points), severe renal disease (e.g., glomerular 
filtration rate <30 ml/min or dialysis-dependent, 3 points), age ≥75 years (2 points), prior 
bleeding (1 point), and hypertension (1 point). Major hemorrhage rates were 0.8% for 
low risk (0 to 3 points), 2.6% for intermediate risk (4 points), and 5.8% for high risk (5 
to 10 points) (Fang et al., 2011). The differences between each risk prediction score is 









 Table 5: Risk Prediction Scores 
TIA, transient ischemic attack; NSAIDs, non-steroidal anti-inflammatory drugs 
Adapted from Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral 
Anticoagulants, AJGSup (Abraham, 2016). 
 
 
Risk elements HAS-BLED HEMORR2HAGES ATRIA 
Hypertension 1 point 1 point 1 point 
Age  1 point (≥65 years) 1 point (≥75 years) 2 points (≥75 
years) 
Prior stroke/ TIA 1 point 1 point  
Chronic liver 
disease, cirrhosis 
1 point 1 point  
Chronic renal 
insufficiency 
1 point 1 point 3 points  
Alcoholism 1 point 1 point  
Malignancy  1 point  
Thrombocytopenia/ 
antiplatelet use 
 1 point  
Prior bleeding 
event 
 2 points 1 point 
Anemia  1 point 3 point 
History of falls  1 point  
Genetic factors   1 point  
Prior bleeding 
events/ anemia 
1 point   
Time to therapeutic 
range <60% 





1 point   
Low risk 0 0-1 0-3 
Intermediate risk 1-2 2-3 4 






1.4 Gastrointestinal Bleeding in Warfarin Anticoagulated Patients 
1.4.1 Incidence 
Upper gastrointestinal bleeding (GIB) is a major emergency situation. It is frequently 
encountered medical emergency with an incidence rate of 72 per 100,000 in Malaysia 
(Ministry of Health Malaysia, 2003). Over the past decade, there seems to have overall 
reduction in number of GIB event leading to hospitalisation with decreasing trend in 
upper GIB events. However, the number of lower GIB events is significantly increase 
(Lanas et al., 2009). Despite advancement in medical amenities and resources leading to 
reduction in overall mortality of GIB, the in-hospital case fatality remains at around 10% 
(Ministry of Health Malaysia, 2003; Siau et al., 2017). Mortality related to GIB are 
mainly contributed by advanced age, shock and coexisting illness (Kim et al., 2016).  
GIB not only contribute to increase number of hospitalisation, it is also associated 
with significant morbidity, 30 days mortality and health-care cost (Monteiro et al., 2016). 
According to Cryer et al. in US, patients with upper GI bleeds experienced significantly 
higher 12-month health-resource utilization and costs than patients without upper GI 
bleeds (Cryer et al., 2010). This is also supported by Campbell et al. where they estimated 
the average cost for in-hospital treatment for upper GIB is £2458 (~RM 13,151) per 
patient (Campbell et al., 2015). This is a large burden to the government with inpatient 
stay, endoscopy and red blood cells transfusion as the main cost drivers.  
One of the important risk factors that causing GIB is the usage of anticoagulant. 
Hreinsson et al. stated that aspirin, NSAIDs and warfarin remain the important role in 
acute upper GIB aetiology (Hreinsson et al., 2013). Furthermore, GIB is one of the severe 
bleeding complications of warfarin anticoagulation and occurs in up to 12% of cases 






In large-scale epidemiological studies on patients receiving warfarin, the annual 
incidence of major bleeding complications ranged from 1.1% to 1.5%, gastrointestinal 
sites accounting for 30–60% of the total (Di Minno et al., 2015). 
Although the incidence of upper GIB among the north-Eastern (Terengganu and 
Kelantan) was said to be low due to low incidence of Helicobacter pylori infection 
(Ministry of Health Malaysia, 2003), Lee et al. stated that the absence of H. pylori 
infection may not reduce the risk of peptic ulcer bleeding in the presence of risk factors 
especially offending drugs and elderly (Lee et al., 2014). AF patients were also known to 
have multiple comorbids and polypharmacy that further predispose to GIB. From Bashir 
et al. study, they found out that among Malaysian people who are on anticoagulant and 
developed clinically relevant bleeding events, the highest number of bleeding 
predominantly from the GIB (Beshir et al., 2018).  
 
1.4.2 Risk Factors 
Most AF patients because of a history of coronary arterial disease (CAD) or 
cerebrovascular disease, low-dose aspirin and/or clopidogrel are often employed in older 
individuals. Especially when low-dose aspirin and/or clopidogrel are combined with 
warfarin, the capability of these drugs to act cumulatively as to the risk of GIB is well 
known (Hansen et al., 2010). Other risk factors include concomitant usage of anti-
depressant, NSAIDs, elderly age and other co-morbidities (Chen et al., 2014; Hernandez-
Diaz and Rodriguez, 2002; Kim et al., 2014; Monteiro et al., 2016). As expected, the 
annual incidence of GIB increased with an increased baseline of HAS-BLED score. 
Figure 3 showed the annual incidence of GIB requiring transfusion increased from 






a baseline HAS-BLED score of 2, and to 1.13%/year for those with baseline HAS-BLED 










Figure 3: Kaplan-Meier estimates of gastrointestinal haemorrhage-free survival in AF 
patients receiving warfarin across different strata of the HAS-BLED score. 
Adapted from Gastrointestinal haemorrhage in atrial fibrillation patients: impact of 
quality of anticoagulation control (Chan et al., 2015). 
 
1.4.3 Mechanism of warfarin related GIB 
The GIB risk associated with warfarin appears to be related to its systemic 
anticoagulant effects via inhibition of key vitamin K–dependent clotting factors, and thus 
varies as a function of the international normalized ratio. Although the mechanism is 
unclear, the relative deficiency in vitamin K dependent clotting factors causing bleeding 










Treatments can be divided into general and specific treatments. Acute treatment 
when patients presented to casualty includes resuscitation, administration of blood 
products and IV pantoprazole infusion. Treatment for reversal of vitamin K antagonist is 
also warranted by either transfusion of fresh frozen plasma (FFP), prothrombin complex 
concentrates (PCC), administration of recombinant activated factor VIIa (rFVIIa) or/and 
administration of vitamin K (Figure 4) to antagonize the VKA anticoagulation effect. 
Vitamin K can be given orally or intravenously, with the parenteral route having the 
advantage of a more rapid onset of action (Crowther et al., 2002).  
After intravenous administration of vitamin K, the INR will start to drop within 2 
hours and will be normalized within 12-16 hours (Lubetsky et al., 2003), whereas after 
oral administration it will take up to 24 hours to normalize the INR. While low (1-2.5 mg) 
to moderate (2.5-5 mg) doses of vitamin K given orally are indicated for the management 
of non-emergency bleeding, slow intravenous infusion of 10 mg vitamin K should be 
given in emergency situations (Radaelli et al., 2015). Higher doses of vitamin K are 
equally effective but may induce resistance to VKAs for more than 1 week, and are 
therefore not recommended (Rubboli et al., 2011). 
 Specific treatment includes endoscopic treatment in order to locate the site of 
bleeding and stop the bleeding. Early endoscopy (within 24 hours) for evaluation and 
therapy in patients with active GIB is both warranted and safe (Abraham and Castillo, 
2013). The most common etiologies for upper GI blood loss in these patients are peptic 
ulcer disease and erosive diseases of the esophagus, stomach, and duodenum. Diverticular 







Considering the recognized benefits of early endoscopy in acute upper GI 
bleeding, various authors have recommended that endoscopy should not be postponed to 
correct coagulopathy in patients with an INR ≤2.5 (Barkun et al., 2010). Rockall score 
assessment can be used to identify 15% of all cases with acute upper gastrointestinal 
haemorrhage at the time of presentation and 26% of cases after endoscopy who are at low 
risk of rebleeding and negligible risk of death who might therefore be considered for early 
discharge or outpatient treatment with consequent resource savings (Rockall et al., 1996). 
 In those with chronic liver disease, administration of infusion octreotide or 
somatostatin are also important. In patients whose bleeding cannot be stop by endoscopic 
intervention, they might require emergency surgery, or catheter angiography with 
embolization by intervention radiologist. Colonoscopy is recommended for patients with 
hematochezia and a negative upper endoscopy unless other source of bleeding have been 





   






Acute GI Bleeding 
Urgent clinical assessment and resuscitation, including blood type & cross-match for active and significant bleeding 
Complete blood count/ clotting screen (INR, aPTT, fibrinogen) 
Active bleeding/ Shock (1) 
1. Stop VKA 
2. Actively reverse anticoagulation:  
-Vitamin K (5-10mg IV infusion over 30 minutes) 
-PCC 25-50 IU/kg according to baseline INR 
value* 
3. Check INR 20-30 minutes after PCC infusion: 
 
1. Stop VKA 
2. Actively reverse anticoagulation:  
-Vitamin K (5-10mg IV infusion over 30 minutes) 
 












 Consider emergent endoscopy preferable when 
INR <2.5 
No further action 
Consider urgent 
endoscopy  
























oral or 1mg 
IV) 
-Recheck clotting screen at 24 hours, or 
sooner if clinical deterioration. 
-Consider endoscopy evaluation as appropriate 
Significant bleeding without haemodynamic 
compromise (2) 
 
Minor rectal bleeding (3) 
Figure 4: Management algorithm for acute GIB on vitamin K antagonists aPTT, activated partial thromboplastin time; PCC, prothombin complex concentrate; INR, 
international normalized ratio; IU, international unit. *Administer 15 mL/kg FFP only if PPC is unavailable. (1) Overt acute GI bleeding (haematemesis, maelena, 
haematochezia), with shock or persistent/intermittent haemodynamic instability. (2) Overt acute GI bleeding but no haemodynamic compromise. (3) Scanty, self-limited 
haematochezia, with neither anaemia nor haemodynamic compromise. 






1.4.5 Outcome Following Gastrointestinal Bleeding In Patients Taking Oral 
Anticoagulants 
In Pourafkari et al. (2017), patients with AF on anticoagulant had hospital 
mortality of 9.8% with upper GIB. Older age and previous history of peptic ulcer disease 
were the predictors of upper GIB in patients with excessive warfarin anticoagulation. 
(Pourafkari et al., 2017) According to Manatsathit et al., mortality rates are much lower, 
3.8% with mean INR level of 2.54 was (±0.3) (Manatsathit et al., 2014). Mortality rates 
are higher in patients with recurrent GIB and supratherapeutic INR level (≥4.0) (Rubin et 
al., 2003). 
In those AF patients with GIB and restarted on warfarin, the outcomes were 
stratified by duration of warfarin interruption, restarting warfarin after 7 days was not 
associated with increased risk of GIB but was associated with decreased risk of mortality 
and thromboembolism compared with resuming after 30 days of interruption. Decision to 
restart warfarin after an episode of major GIB is associated with improved survival and 
decreased thromboembolism without increased risk of GIB after 7 days of interruption 
(Qureshi et al., 2014). Anticoagulation is often stopped after the acute bleeding event, but 
restarting anticoagulation at discharge after the index event was associated with fewer 
thromboembolic events without a significantly increased risk of recurrent gastrointestinal 
haemorrhage at 90 days (Sengupta et al., 2015).  
1.4.6 Resuming anticoagulant following GIB 
The main parameters to take into consideration when restarting anticoagulant are 
the risk of recurrent bleeding and the thromboembolic disease of the underlying disease 
for which anticoagulant was prescribed before the bleeding event. In fact, American 






anticoagulant if the thromboembolic risk exceed the risk of recurrent bleeding. This 
means that every case should be individualised and a common decision among the 
gastroenterologist and cardiologist should be reached, based on the history and 
indications for each particular patient (Anderson et al., 2009). 
 The risk of recurrent bleeding could not be predicted with accuracy. If 
endoscopy findings of peptic ulcers with clean based, the risk can be as low as less than 
5% as compared to those with signs of recent haemorrhage stigmata, recurrence may be 
as high as 55% (Elmunzer et al., 2008). Several scoring system has been proposed to 
calculate the gastrointestinal re-bleeding risk (e.g Blatchford, Rockall and Baylor 
College). According Laursen et al. they found that Glasgow Blatchford Score (GBS) 
accurately identifies patients with upper GIB most likely to need hospital-based 
intervention and also best suited for outpatient care. No scoring system seems to 
accurately predict patients’ 30-day mortality or rebleeding (Laursen et al., 2012). Both 
GBS and Rockall score are illustrated in table 6 and 7.  
Apart from that, the decision to resume anticoagulant also depends on patients’ 
thrombotic risk as a result of anticoagulant discontinuation. Based on CHA2DS2 VASc 
score the stroke risk is as high as >9% in those with score of ≥6. According to Chatree et 
al., the thromboembolic event occurred in 9.9% of those who resume warfarin compared 
to 16.4% who did not. Recurrent GIB occurred in 10.1% resuming warfarin compared to 
5.5% who did not. Resumption of warfarin leads to significant reduction in mortality 
(Chai-Adisaksopha et al., 2015).  
 
 
 
